AbbVie welcomes the Commissions targeted revision of the MDR/IVDR and appreciates the intent to update Regulation (EU) 2017/745 based on practical experience and broadly supports many of the Commissions proposals. These proposals introduce important measures to support innovation and improve regulatory efficiency, however, there is room for further improvement on several aspects.
ABB
AbbVie
Company · Belgium · EU Transparency Register 934069612666-51
3
positions filed
in the 583 files tracked
3
legislative files
of 583 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1048 companies & groups on this site, they rank #356 by legislative files engaged — a count of participation, not a measure of influence.
2.5
declared lobbying FTE
self-declared
€1M+
declared costs / yr (floor)
5
EP accreditations
as declared to the register
2014
in the register since
Declares membership of
- American Chamber of Commerce to the EU →
- European Federation of Pharmaceutical Industries and Association (EFPIA)
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026).
- Register category
- Companies & groups
- Head office
- North Chicago, United states
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track AbbVie in PolicySpeak: request access →
Work at AbbVie? so we know who speaks for it.
Their record over time
AbbVie filed 3 positions between 6 Jan 2021 and 3 Aug 2026, across 3 of the 583 legislative files tracked here.
2021 · 2 filed2026 · 1 filed
What they argued
As a research-driven biopharmaceutical company, AbbVie supports the Commission objectives to create a patient-centered and globally competitive European pharmaceutical policy environment that enhances the availability of medicines across the EU and incentivizes development of treatments for unmet health needs in both diseases where no treatments exist as well as those where the existing treatments do not…
As an innovative biopharmaceutical company with over 11.000 employees in the EU, AbbVie supports the Commission’s aims to develop more medicines for unmet needs, speed access to new therapies for all EU citizens, and ensure the maximum benefits from scientific and technological advances.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put AbbVie next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Showing 5 of 80.
Is this your organization?
Everything on this page comes from AbbVie’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.